AGI Therapeutics plc Says FDA Accepts New Drug Filing for IBS Treatment Arverapamil

LONDON (Thomson Financial) - AGI Therapeutics PLC said the US Food and Drug Administration has accepted its investigational new drug filing for a late-stage study of arverapamil, a treatment for diarrhoea-predominant irritable bowel syndrome.